Can Zostum (cefoperazone‑sulbactam) be administered intravenously to a 6‑month‑old infant (~7.5 kg) with no β‑lactam allergy and acceptable renal function?

Zostum (Cefoperazone-Sulbactam) is NOT Recommended for Routine Use in a 6-Month-Old Infant

Zostum (cefoperazone-sulbactam) should not be used as a first-line agent in a 6-month-old infant, as it is not included in any major pediatric treatment guidelines and superior alternatives with established safety profiles are readily available.

Why Zostum is Not the Preferred Choice

Absence from Guideline Recommendations

The most recent and authoritative pediatric infectious disease guidelines do not list cefoperazone-sulbactam as a recommended agent for any common pediatric infection:

• For febrile infants (8-60 days): Guidelines recommend ceftriaxone, ceftazidime, ampicillin, or gentamicin—not cefoperazone-sulbactam 1

• For complicated intra-abdominal infections: Acceptable regimens include piperacillin-tazobactam, carbapenems (imipenem, meropenem, ertapenem), or advanced cephalosporins (cefotaxime, ceftriaxone, ceftazidime, cefepime) with metronidazole 2

• For community-acquired pneumonia: Standard therapy involves ampicillin, ceftriaxone, or cefotaxime 3

Limited Pediatric Safety Data

While older Japanese studies from 1984 demonstrate that cefoperazone-sulbactam can be administered to children at doses of 56-320 mg/kg/day divided into 3-4 doses 4, 5, 6, 7, these studies:

• Are over 40 years old
• Involve small patient numbers (18-43 patients)
• Lack the rigorous safety monitoring standards of modern trials
• Have not been replicated in contemporary Western literature

The most recent pharmacokinetic study (2025) provides dosing guidance but emphasizes the need for extended infusions (4 hours) at high doses (60 mg/kg four times daily) for nosocomial pathogens 8—a complex regimen not practical for routine use in infants.

What to Use Instead

For Common Pediatric Infections in a 6-Month-Old:

Urinary Tract Infection:

• Ceftriaxone 50 mg/kg IV/IM once daily 1

Suspected Bacteremia (no focus identified):

• Ceftriaxone 50 mg/kg IV/IM once daily 1

Community-Acquired Pneumonia:

• Ampicillin 150-200 mg/kg/day IV divided every 6 hours, OR
• Ceftriaxone 50-75 mg/kg/day IV every 12-24 hours 2, 3

Complicated Intra-Abdominal Infection:

• Piperacillin-tazobactam 200-300 mg/kg/day (of piperacillin component) IV every 6-8 hours, OR
• Cefotaxime 150-200 mg/kg/day IV every 6-8 hours plus metronidazole 30-40 mg/kg/day IV every 8 hours 2

Critical Caveats

When Cefoperazone-Sulbactam Might Be Considered:

Only in highly specific circumstances where:

1. Multidrug-resistant organisms are documented (particularly ESBL-producing Enterobacterales) AND
2. First-line agents have failed or are contraindicated AND
3. Susceptibility testing confirms activity AND
4. Infectious disease consultation has been obtained

Even then, recent adult data show cefoperazone-sulbactam is effective primarily when MIC ≤32/32 mg/L 9, and coagulation dysfunction occurs in 24% of patients, requiring vitamin K monitoring 10.

The FDA Label Issue:

The FDA label you referenced 11 is for veterinary use only (acepromazine, a veterinary tranquilizer)—this is not the human formulation of cefoperazone-sulbactam and provides no guidance for pediatric use.

Bottom Line Algorithm

For a 6-month-old infant with bacterial infection:

1. Identify the infection source (UTI, pneumonia, bacteremia, etc.)
2. Use guideline-recommended first-line agents (ceftriaxone, ampicillin, piperacillin-tazobactam, or cefotaxime based on source)
3. Reserve cefoperazone-sulbactam only for documented resistant organisms after ID consultation
4. Never use the veterinary formulation

The evidence strongly supports using established, guideline-recommended antibiotics rather than cefoperazone-sulbactam for routine pediatric infections in this age group.